NIDDK Central Repository - Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1007/s10620-012-2512-x

PubMed ID

23325162

Public Release Type

Journal

Publication Year

2013

Affiliation

Division of Gastroenterology and Hepatology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305-5187, USA. sundeeps@stanford.edu

Authors

Acute Liver Failure Study Group, Hynan LS, Lee WM, Singh S

Studies

AALF

Citation

Singh S, Hynan LS, Lee WM, Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013 May;58(5):1397-402. Epub 2013 Jan 17.

Abstract

N-acetylcysteine (NAC) improves transplant-free survival in early coma grade (I-II) patients with non-acetaminophen induced acute liver failure (ALF). We determined whether the clinical benefit was associated with improvements in hepatic function.